Jones Gregory T, Kay I Patrick, Chu J W S, Wilkins G T, Phillips L V, McCormick M, van Rij A M, Williams M J A
Section of Surgery, University of Otago, Dunedin, New Zealand.
Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):e121-5. doi: 10.1161/01.ATV.0000226544.93089.7f. Epub 2006 May 11.
This study aimed to determine whether the plasma levels of matrix metalloproteinase-9 (MMP-9) or tissue inhibitor of metalloproteinases-1 (TIMP-1) were altered in patients with a history of symptomatic in-stent restenosis (ISR).
A group of 158 patients with a history of ISR were compared with 128 symptom-free patients. Plasma samples and a detailed risk factor history were collected. Plasma samples were analyzed for pro-MMP-9 and latent MMP-9 and active MMP-9, latent MMP-3, and TIMP-1. Several variables were associated with ISR, including index coronary disease extent and severity (number of diseased vessels and American College of Cardiology/American Heart Association lesion classification), number, diameter, and total length of stent(s) inserted, and plasma high-density lipoprotein cholesterol. Plasma active MMP-9 (odds ratio, 1.96; 95% CI, 1.43 to 2.69) showed independent risk association with ISR. Patients with multiple sites of ISR had significantly higher levels of active MMP-9 compared with patients with only a single ISR lesion or no ISR.
Plasma active MMP-9 levels may be a useful independent predictor of bare metal stent ISR.
本研究旨在确定有症状的支架内再狭窄（ISR）病史的患者血浆基质金属蛋白酶-9（MMP-9）或金属蛋白酶组织抑制剂-1（TIMP-1）水平是否发生改变。
将一组158例有ISR病史的患者与128例无症状患者进行比较。收集血浆样本和详细的危险因素病史。分析血浆样本中的前MMP-9、潜伏MMP-9和活性MMP-9、潜伏MMP-3以及TIMP-1。有几个变量与ISR相关，包括索引冠状动脉疾病的范围和严重程度（病变血管数量和美国心脏病学会/美国心脏协会病变分类）、插入支架的数量、直径和总长度，以及血浆高密度脂蛋白胆固醇。血浆活性MMP-9（比值比，1.96；95%可信区间，1.43至2.69）显示与ISR存在独立风险关联。与仅有单个ISR病变或无ISR的患者相比，多个ISR部位的患者活性MMP-9水平显著更高。
血浆活性MMP-9水平可能是裸金属支架ISR的一个有用的独立预测指标。
